Literature DB >> 22323558

Xenoepitope substitution avoids deceptive imprinting and broadens the immune response to foot-and-mouth disease virus.

Steven M Szczepanek1, Roger W Barrette, Debra Rood, Diana Alejo, Lawrence K Silbart.   

Abstract

Many RNA viruses encode error-prone polymerases which introduce mutations into B and T cell epitopes, providing a mechanism for immunological escape. When regions of hypervariability are found within immunodominant epitopes with no known function, they are referred to as "decoy epitopes," which often deceptively imprint the host's immune response. In this work, a decoy epitope was identified in the foot-and-mouth disease virus (FMDV) serotype O VP1 G-H loop after multiple sequence alignment of 118 isolates. A series of chimeric cyclic peptides resembling the type O G-H loop were prepared, each bearing a defined "B cell xenoepitope" from another virus in place of the native decoy epitope. These sequences were derived from porcine respiratory and reproductive syndrome virus (PRRSV), from HIV, or from a presumptively tolerogenic sequence from murine albumin and were subsequently used as immunogens in BALB/c mice. Cross-reactive antibody responses against all peptides were compared to a wild-type peptide and ovalbumin (OVA). A broadened antibody response was generated in animals inoculated with the PRRSV chimeric peptide, in which virus binding of serum antibodies was also observed. A B cell epitope mapping experiment did not reveal recognition of any contiguous linear epitopes, raising the possibility that the refocused response was directed to a conformational epitope. Taken together, these results indicate that xenoepitope substitution is a novel method for immune refocusing against decoy epitopes of RNA viruses such as FMDV as part of the rational design of next-generation vaccines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22323558      PMCID: PMC3318270          DOI: 10.1128/CVI.00035-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  41 in total

1.  Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines.

Authors:  Rana A K Singh; Michael A Barry
Journal:  J Immunol       Date:  2004-10-01       Impact factor: 5.422

2.  Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants.

Authors:  J W Stave; J L Card; D O Morgan; V N Vakharia
Journal:  Virology       Date:  1988-01       Impact factor: 3.616

3.  Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate.

Authors:  G A Mayr; J Chinsangaram; M J Grubman
Journal:  Virology       Date:  1999-10-25       Impact factor: 3.616

Review 4.  Biochemical and structural studies with neutralizing antibodies raised against foot-and-mouth disease virus.

Authors:  E Domingo; N Verdaguer; W F Ochoa; C M Ruiz-Jarabo; N Sevilla; E Baranowski; M G Mateu; I Fita
Journal:  Virus Res       Date:  1999-08       Impact factor: 3.303

5.  Comparison of the major antigenic determinants of different serotypes of foot-and-mouth disease virus.

Authors:  A Cheung; J DeLamarter; S Weiss; H Küpper
Journal:  J Virol       Date:  1983-11       Impact factor: 5.103

6.  Identification of neutralizing and nonneutralizing epitopes in the porcine reproductive and respiratory syndrome virus GP5 ectodomain.

Authors:  M Ostrowski; J A Galeota; A M Jar; K B Platt; F A Osorio; O J Lopez
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  The cell attachment site on foot-and-mouth disease virus includes the amino acid sequence RGD (arginine-glycine-aspartic acid).

Authors:  G Fox; N R Parry; P V Barnett; B McGinn; D J Rowlands; F Brown
Journal:  J Gen Virol       Date:  1989-03       Impact factor: 3.891

8.  Identification of an exposed region of the immunogenic capsid polypeptide VP1 on foot-and-mouth disease virus.

Authors:  B H Robertson; D M Moore; M J Grubman; D G Kleid
Journal:  J Virol       Date:  1983-04       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

Authors:  J Goudsmit; C Debouck; R H Meloen; L Smit; M Bakker; D M Asher; A V Wolff; C J Gibbs; D C Gajdusek
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

10.  Intranasal immunization of guinea pigs with an immunodominant foot-and-mouth disease virus peptide conjugate induces mucosal and humoral antibodies and protection against challenge.

Authors:  D Fischer; D Rood; R W Barrette; A Zuwallack; E Kramer; F Brown; L K Silbart
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  1 in total

1.  The level of decoy epitope in PCV2 vaccine affects the neutralizing activity of sera in the immunized animals.

Authors:  Junyeong Jin; Changhoon Park; Sun-Hee Cho; Junho Chung
Journal:  Biochem Biophys Res Commun       Date:  2018-01-31       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.